About this event

ASCO Genitourinary Cancers Symposium (#GU27) – Deep Research Analysis

Event Basics (Extracted from Official Website)

• Event name: ASCO Genitourinary Cancers Symposium (#GU27)
• Dates: February 11–13, 2027
• Venue: Moscone West
• City/Region: San Francisco, CA
• Format: In-person and Online (online-only attendees are supported for CME/MOC claiming and access)

Why This Symposium Matters (Context We Use for Buyer Targeting)

The ASCO Genitourinary Cancers Symposium is an oncology-focused scientific and clinical education meeting centered on genitourinary cancers. Because the program includes paradigm-shifting research translation into practice, the audience typically includes medical leaders, academic and research oncologists, and industry stakeholders who track emerging therapies, clinical trial findings, and evidence-based treatment guidance.

The meeting also includes a dedicated exhibitor presence (620 exhibitors listed), along with strong international representation (57 countries represented), which makes it suitable for attendee/participant discovery and networking-driven outreach. In addition, the symposium spans both physical and virtual participation, expanding access for geographically diverse professionals.

1️⃣ Who Attends (Buyers / Attendees)

This is not structured like a consumer trade show. It functions as a clinician-researcher-industry convergence event. Accordingly, the “buyer” profiles that tend to matter most usually fall into the following categories (we refer to these as buyers because they influence evaluation, adoption, budgets, partnerships, clinical trial collaboration, and technology/solution selection):

A) Core attendee groups

• Medical oncologists and urologic oncology clinicians who evaluate emerging standards of care.
• Academic researchers translating trial endpoints, biomarkers, and translational science into practice.
• Clinical trial leadership teams (clinical operations, protocol teams, investigator networks).
• Pathology and diagnostic-facing specialists who connect biomarker development to clinical workflows.
• Pharmacovigilance and medical affairs professionals who interpret evidence and support appropriate use.
• Oncology nurses and advanced practice providers involved in care delivery and patient pathways.
• Regulatory and health economics stakeholders focused on evidence packages, access considerations, and outcomes data.

B) Buyer-side (high-fit) profiles we often target

• Medical Affairs Directors / Heads of Medical Affairs (therapy strategy, evidence planning, KOL alignment).
• Clinical Operations Leaders (trial execution, vendor/service partner selection, site operations strategy).
• Clinical Research Directors (protocol leadership, translational research alignment).
• Translational Science / Biomarker Program Leaders (diagnostics and biomarker enablement).
• Market Access & Outcomes / HEOR leadership (real-world evidence, value dossiers, payer discussions).
• Regulatory Affairs leadership for global submissions and label/evidence alignment.
• Exhibitor representatives tied to products, services, and innovation pipeline (not just booth foot traffic).

2️⃣ Where the Show Is Happening + Attendee Geographic Origin

Show location

The in-person component is held at Moscone West in San Francisco, CA.

Geographic origin (international reach signals from the event)

The official site indicates 57 countries represented, including the U.S., Canada, Brazil, Germany, and Japan. That provides a strong baseline for international participant composition, with the largest share typically coming from North America and Europe due to ASCO’s strong global network and the specialized clinical community involved.

How we translate this into targeting

• Primary geographic emphasis: United States and Canada (strong likelihood of institutional participation).
• High-probability international markets: Germany, Japan, Brazil (explicitly named on the official site), plus broader Europe and APAC.
• Virtual extension effect: Because the symposium supports online-only attendees, we can also capture organizations whose teams cannot travel, but still engage digitally with the scientific program and exhibitor ecosystem.

3️⃣ Audience Reach (Local / National / Global)

This event operates at a global scientific-reach level. The official website provides three key reach signals:

• Total attendees: 5,850
• Countries represented: 57
• Exhibitors: 620

While the physical venue is San Francisco (local host city), the audience is clearly international by design. The combination of global representation and a high exhibitor count supports strong cross-border networking and business discussion.

4️⃣ Sample Buyer Company Names + Websites (BUYERS ONLY)

Below are example buyer-side company accounts we would typically consider for lead alignment based on the symposium’s oncology, genitourinary-cancer focus, and the exhibitor ecosystem. These are samples to demonstrate how we structure our “buyer fit” outreach.

Important: To refine this list precisely for your product and to ensure the best buyer match, we need your client product details (see Section 8).

Sample Buyer List Table (15–20 records)

Priority	Company	Website	Best Title to Target	Why This is a Good Buyer Fit
1	Daiichi Sankyo, Inc.	https://www.daiichisankyo.com/	Medical Director / Head of Medical Affairs	As a listed sponsor donor (Gold), aligns with therapy evidence evaluation and clinical education engagement around oncology and treatment innovation.
2	Novartis	https://www.novartis.com/	Director, Medical Affairs / Oncology Evidence Lead	Listed as a Visionary donor; typically supports clinical strategy, evidence communications, and medical/clinical partnerships relevant to GU oncology.
3	Exelixis, Inc.	https://www.exelixis.com/	Clinical Operations Director / Head of Clinical Trials	Listed as an Innovator donor; strong fit for clinical trial collaboration, evidence generation, and translational/oncology engagement.
4	Lantheus	https://www.lantheus.com/	Director, Diagnostic Strategy / Medical Imaging & Diagnostics Lead	Listed as an Innovator donor; diagnostics and imaging capabilities often intersect with biomarker-driven oncology care.
5	UroGen Ltd.	https://urogen.com/	Medical Affairs Lead / Clinical Development Director	Listed as an Innovator donor; a high-likelihood fit for GU cancer innovation, clinical program updates, and evidence translation.
6	Pfizer Oncology	https://www.pfizer.com/	Head of Clinical Development / Director, Clinical Research	Large oncology pipeline teams commonly participate in ASCO symposia to align clinical development strategy with evolving standards.
7	Bristol Myers Squibb	https://www.bms.com/	Medical Director, Oncology / Evidence & Outcomes Lead	Oncology-focused teams frequently engage with GU cancer evidence and care pathway adoption, especially through medical affairs and HEOR.
8	Merck (MSD)	https://www.merck.com/	Director, Medical Affairs / Oncology Clinical Strategy	Oncology leaders commonly sponsor and support ASCO meetings; medical strategy and evidence planning align strongly with symposium themes.
9	Astellas Pharma	https://www.astellas.com/	Head of Clinical Research / Urology Oncology Program Lead	Astellas’ urology/onco presence typically intersects with GU cancer therapeutics and clinical collaboration needs.
10	Janssen (Johnson & Johnson)	https://www.janssen.com/	Director, Clinical Operations / Medical Affairs Lead	Oncology medical and clinical operations teams align with ASCO education and evidence exchange, especially for GU malignancies.
11	Sanofi	https://www.sanofi.com/	Oncology Program Director / HEOR & Access Lead	Sanofi teams often engage in oncology congresses with outcomes, access considerations, and therapy evidence refinement.
12	Guardant Health	https://guardanthealth.com/	Director, Clinical Partnerships / Biomarker Program Lead	Biomarker and genomic testing aligns directly with GU cancer precision approaches and trial matching needs.
13	Foundation Medicine	https://www.foundationmedicine.com/	Head of Clinical Evidence / Strategic Partnerships	Precision oncology diagnostics teams often participate in evidence-driven oncology symposiums for biomarker adoption and KOL engagement.
14	IQVIA	https://www.iqvia.com/	Director, Oncology Research / HEOR Engagement Lead	Supports evidence generation, real-world insights, and outcomes research that connect to oncology decision-making.
15	ICON plc	https://www.iconplc.com/	Vice President, Clinical Operations / Director, Clinical Trials	Clinical research services providers strongly align with symposium ecosystems due to the volume of trial activity and vendor partner selection.
16	CRO / Clinical Research Services (Example: Parexel)	https://www.parexel.com/	Director, Clinical Development / Site Network Strategy Lead	Typical buyer profiles at oncology symposia include trial network leadership, protocol development influence, and partner selection.
17	Medidata (Dassault Systèmes)	https://www.medidata.com/	Life Sciences Partnerships Director / Clinical Data Platform Lead	Digital clinical trial and data platforms align with how sponsors evaluate and operationalize clinical evidence generation.
18	Flatiron Health (Tempus ecosystem)	https://www.flatiron.com/	Director, Real-World Evidence / Oncology Data Partnerships	Real-world evidence and oncology data teams frequently intersect with symposium discussions and translational evidence needs.

Top Buyer Targets to Prioritize (Recommended First Send)

We recommend prioritizing sponsor-aligned and GU-oncology-aligned accounts first because they tend to have internal teams dedicated to symposium participation, medical affairs engagement, clinical evidence dissemination, and exhibitor scheduling:

• Daiichi Sankyo
• Novartis
• Exelixis
• Lantheus
• UroGen

5️⃣ Job Profiles, Industries & Event Type

Event type classification

We classify this as a medical/scientific conference with an exhibitor & sponsor ecosystem, focused on oncology education, clinical research translation, and practice advancement. The event supports continuing education mechanics (CME/MOC) for both in-person and online attendees.

Job profiles (high-probability buyer titles in Apollo-style filtering)

• Chief Medical Officer / Senior Medical Director (evidence strategy)
• Director, Medical Affairs (clinical engagement and education alignment)
• Clinical Development Director / Head of Clinical Trials
• Vice President, Clinical Operations
• Director, Translational Medicine / Biomarker Program Lead
• HEOR / Market Access Director (outcomes, value, access)
• Regulatory Affairs Director (evidence dossiers and compliance)
• Oncology Product Manager / Therapy Portfolio Lead
• Clinical Data / Platform Product Leads (digital trial/data infrastructure)
• Pathology / Diagnostics Medical Director (diagnostic validation and integration)
• Exhibitor Operations / Partnering Manager (symposium participation and lead workflow)

Industries to emphasize (from the provided industry list)

Based on the symposium topic (genitourinary cancers, clinical education, research, diagnostics, oncology therapies), we would prioritize industries most likely to contain relevant buyer roles:

• Pharmaceuticals
• Medical Devices
• Hospital & Health Care
• Biotechnology
• Research
• Market Research
• Information Technology & Services
• Computer Software (for clinical data, trial platforms, analytics, evidence tooling)
• Hospitality (lower relevance for buyers, but still present due to large conference operations)
• Events Services (often relevant for exhibit/sponsorship vendors rather than clinical buyers)

6️⃣ Estimated Attendance (Expected Total Footfall)

The official symposium page lists:

• Total attendees: 5,850
• Exhibitors: 620

Because the event supports both in-person and online viewing, actual physical footfall may be lower than the combined total attendance figure, but the exhibitor ecosystem typically remains concentrated around the in-person conference footprint while also generating digital engagement.

7️⃣ Key Focus Areas & Buyer Engagement

Primary content themes (inferred from event positioning)

• Paradigm-shifting discoveries and translation into transformative patient care.
• Genitourinary cancer standards of care (treatment planning and clinical best practices).
• Clinical trial evidence, including updates that influence research direction and clinical adoption.
• Evidence-based care pathways, including how treatments are sequenced and optimized.

How buyers engage at events like #GU27

We typically see buyer engagement concentrated in a few predictable areas that help outreach messaging stay relevant:

• Medical education & evidence interpretation (buyers who want to support adoption or alignment).
• Clinical trial operations & infrastructure (CRO/platform/execution partners).
• Diagnostics and biomarker enablement (diagnostic validation, integration into workflows).
• Patient impact narratives tied to outcomes and real-world adoption.
• Exhibitor booth strategy (appointments, meetings, and follow-ups with KOL-facing teams).

Best-fit outreach positioning

• Lead with GU oncology relevance (not generic oncology).
• Use evidence + operational readiness framing (fits medical affairs and clinical operations buyer psychology).
• Align with translation: how research becomes care, how data becomes decisions, how diagnostics becomes action.

8️⃣ Client Product Fit Review Request (We Need Your Website)

We can produce the best buyer list for this symposium, but we must match the attendee/buyer types to your client’s actual offering. The official event audience includes clinical and research decision-makers as well as sponsor/exhibitor buyer stakeholders, so the correct titles/companies depend heavily on what your client sells.

Please share your client website URL (or product name + landing page). Then we will:

• Identify which of the following buyer categories your client most directly supports:
  • Therapy/medical communications buyers (medical affairs)
  • Trial enablement buyers (clinical operations, CRO leadership)
  • Diagnostics/biomarker workflow buyers
  • HEOR/market access buyers
  • Clinical data/digital platform buyers
• Recommend the highest priority company segments to target among exhibitors and sponsor-aligned organizations.
• Provide an optimized buyer title list (specific job functions to use for outreach targeting).
• Validate fit against #GU27 themes and exhibitor density (620 exhibitors) to maximize meeting relevance.

Until we review the client website, we can only provide a structured sample and buyer-fit framework (like the table above) rather than the final “best buyers” list tailored to your exact requirement.

9️⃣ Final Recommendation (Is #GU27 Worth Targeting?)

Yes—ASCO Genitourinary Cancers Symposium (#GU27) is a strong conference for buyer-fit outreach and high-quality audience discovery. The official page confirms:

• High relevance to oncology decision-making and evidence-driven care
• Strong scale with 5,850 total attendees
• Large exhibitor ecosystem with 620 exhibitors
• Global composition with 57 countries represented
• Hybrid access (in-person and online-only attendees)

Our recommended buyer shortlist approach for maximum conversion is:

• Step 1: Start with sponsor-aligned organizations and GU-oncology-relevant therapy/diagnostics leaders.
• Step 2: Add clinical trial ecosystem buyers (CROs, clinical operations leaders, digital clinical platforms).
• Step 3: Include biomarker/diagnostics and outcomes/market access teams that connect evidence to adoption.
• Step 4: Filter job titles to align with evaluation, procurement influence, and partnership decision-making.

Quick Clarifying Questions (So We Can Deliver the Best Buyer List)

• What is the client website (URL) we should review?
• Is the product mainly for pharma/biotech, clinics/hospitals, or research/CRO ecosystems?
• Which outreach outcome is most important: partnership meetings, pilot adoption, vendor onboarding, or sales conversations?
• Any geographic constraints (e.g., US-only, North America + Europe, or global)?

Once we receive the client website, we will refine the sample above into a high-priority buyer list tailored to your product’s best-fit buyer roles and industries for #GU27.